Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Emergex Vaccines Holding Limited is currently engaged in the prosecution of a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action, which represents the current active workload at the USPTO. This indicates that the company's legal efforts are focused on a specific technical path rather than a broad array of biotechnology claims. For a practitioner, this concentration means that the success of the current prosecution cycle depends on a single matter.
The prosecution is handled by 1 distinct examiner, JADHAO, SAMADHAN JAISING, who is also the busiest examiner with 1 pending office action. Since the portfolio's active matters are limited to 1 distinct art unit, the prosecution risk is tied to a specific technical review process. This centralized structure simplifies the monitoring of pending Biotechnology & Pharmaceuticals claims for the company. Having 1 distinct examiner allows for a consistent dialogue between the applicant and the USPTO. The 1 distinct art unit involved suggests a narrow and specialized technical focus for the pending application. This structure facilitates a more direct engagement with the USPTO during the examination process.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JADHAO, SAMADHAN JAISING | 1 | 46.2% | +47.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18546586 | REVERSE PEPTIDES FROM CORONAVIRUS FOR IMMUNOGENIC PURPOSES | JADHAO, SAMADHAN JAISING | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18546586 | REVERSE PEPTIDES FROM CORONAVIRUS FOR IMMUNOGENIC PURPOSES | JADHAO, SAMADHAN JAISING | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18546586 | REVERSE PEPTIDES FROM CORONAVIRUS FOR IMMUNOGENIC PURPOSES | JADHAO, SAMADHAN JAISING | 1672 | §101§102§103§112 | Non-Final OA | — | Pending | Aug 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEmergex Vaccines Holding Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Samadhan Jaising Jadhao has the most, with 1 of Emergex Vaccines Holding Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
